Evidence map›Paper›PMID 26696594›Full record

ArticleJournal of cancer research and clinical oncology2016

The association of intravascular stromal cells with prognosis in high-grade neuroendocrine carcinoma of the lung.

Keigo Sekihara, Tomoyuki Hishida, Shinnosuke Ikemura, Koichi Saruwatari, Masahiro Morise, Takeshi Kuwata, Satoshi Fujii, Motohiro Kojima, Atsushi Ochiai, Kazuhito Funai and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Keigo SekiharaDivision of Pathology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Tomoyuki HishidaDivision of Thoracic Surgery, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Shinnosuke IkemuraDivision of Pathology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Koichi SaruwatariDivision of Pathology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Masahiro MoriseDivision of Pathology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Takeshi KuwataDivision of Pathology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Satoshi FujiiDivision of Pathology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Motohiro KojimaDivision of Pathology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Atsushi OchiaiDivision of Pathology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Kazuhito FunaiFirst Department of Surgery, Hamamatsu University School of Medicine, 1-20-1, Handayama, Hamamatsu, Shizuoka, 431-3192, Japan.
Keiju AokageDivision of Thoracic Surgery, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Junji YoshidaDivision of Thoracic Surgery, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Masahiro TsuboiDivision of Thoracic Surgery, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Genichiro IshiiDivision of Pathology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. gishii@east.ncc.go.jp.
National Cancer Center Hospital East · JPHamamatsu University School of Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeHistological vascular invasion (VI) is major predictor of recurrence after surgery for several cancer types. We previously reported that VI with abundant stromal cell infiltrates was a negative prognostic factor in lung adenocarcinoma. This study examined whether stromal cell infiltrates within VI are associated with prognosis in high-grade neuroendocrine carcinoma (HGNEC) of the lung.

methodsWe investigated the relationship between the frequency and density of VI and recurrence-free survival (RFS) of 60 resected HGNEC patients without adjuvant chemotherapy. We examined prognostic effects of CD204 (+) macrophages, CD34 (+) microvessels and α-smooth muscle actin (+) myofibroblasts within VI. Correlation between expressions of stem cell-related molecules (ALDH-1, Notch 1, CD44) and epithelial-mesenchymal transition-related molecules (E-cadherin, S100A4) in cancer cells within VI and RFS was also analyzed.

resultsAmong 60 cases, 51 cases showed VI. Although the presence of VI was a significant predictor for worse RFS (P = 0.04), the frequency and density of VI were not correlated with RFS. The number of CD204 (+) macrophage, CD34 (+) microvessels and α-smooth muscle actin (+) myofibroblasts within VI did not influence on the RFS. On the contrary, cases with higher Notch 1 expression in cancer cells in the VI displayed significantly shorter RFS than lower expression group (7.6 vs. 29.4 months, P = 0.02).

conclusionsThe current study revealed the presence of stromal cells within VI was not significant predictor for recurrence in HGNEC. This suggests that in HGNEC, unlike adenocarcinoma, intravascular stromal cells are not major contributors to metastasis.

Indexed as

ActinsAdenocarcinomaAgedAntigens, CD34Antineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCadherinsCarcinoma, NeuroendocrineChemotherapy, AdjuvantEpithelial-Mesenchymal TransitionFemaleFollow-Up StudiesHumansImmunoenzyme TechniquesLung NeoplasmsMacrophagesACTA2 protein, humanActinsAntigens, CD34Biomarkers, TumorCadherinsMSR1 protein, humanScavenger Receptors, Class AHigh-grade neuroendocrine carcinomaIntravascular microenvironmentLarge cell neuroendocrine carcinomaNotch1Small cell lung cancerStromal cellsVascular invasion

Identifiers

PMID26696594
PMCPMC11819316
OpenAlexW2257332766

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.